|
|
These are some of our latest tests:
|
|
|
| |
|
 |
| |
|
|
Utilities: |
Serial testing shows
that increasing amounts of IgG anti-C1q
predict renal flares in SLE patients. An
increase in serum IgG anti-C1q has sensitivity
of 71% and specificity of 92%. Elevated
serum titers tend to be associated with
proliferative forms of lupus, glomerulonephritis
and subendothelial deposits of immune complexes.
|
Methodology: |
EIA |
Specimen
Requirement: |
1 mL Serum or EDTA Plasma |
| CPT
Code: |
83520 |
Test
#: |
158 |
|
|
|
|
|
|
 |
TOP |
| |
|
|
Utilities: |
Autoimmune inner ear disease
(AIED) is a heterogeneous group of diseases
with regard to clinical presentation and
immunoreactivity to inner ear components.
They include rapidly progressive sensorineural
hearing loss (SNHL), Ménière's
disease (MD), and sudden deafness (SD).
The search for a diagnostic test led to
the finding that most AIED patients had
antibodies that react with 130-kd, 68-
kd, 58-kd, 42-kd and 30-kd (P0) proteins
from human and bovine ears. The presence
of antibodies to a 68-kd antigen, identified
by Western blot, has been the best candidate
to date as a diagnostic test for AIED and
may be useful in predicting steroid responsiveness
in the patient population. Moreover, reactivity
with the 68-kd protein was present in serum
samples from 89% of 47 patients with active
disease compared to none of 25 patients
with inactive disease. Of the 36 patients
with a positive test result on Western
blot assay for antibodies to the 68-kd
protein, 27 (75%) responded to steroid
therapy. Only four (18%) of the 22 patients
with a negative test result responded to
steroid therapy. A recent study showed
a positive reaction to P0 (from guinea
pig inner ear extraction) in all bilateral
MD and bilateral sudden hearing loss patients
and indicates these pathologies are the
result of an ongoing autoimmune process
directed against specific inner ear antigens.
The 68-kd inner ear antigen identified
by Ramakrishnam is not HSP-70. The 68-kd
protein binds supporting cells in the organ
of Corti, while HSP-70 antibody does not
bind to any site in the inner ear. Also,
the commercial recombinant HSP-70 could
not bind to sera from patients with AIED.
This data indicates that the presence
of circulating antibodies to human or bovine
inner ear extract serves as a useful marker
for the diagnosis of AIED and that its
presence correlates with disease activity
and responsiveness to corticosteroid treatment.
RDL has developed a new EIA anti-Bovine
Inner Ear Membrane antibody assay including
130-kd, 68-kd, 42-kd and 30-kd (P0) antibodies. |
Methodology: |
EIA |
Specimen
Requirement: |
1 mL serum, ambient, refrigerated
or frozen |
| CPT
Code: |
83520 |
Test
#: |
259 |
|
|
|
|
|
|
 |
TOP |
| |
|
|
Utilities: |
Neurologic and/or psychiatric
manifestations occur in up to 2/3 of patients
with SLE. The cerebral manifestations are extremely diverse, ranging from
mild depression to severe, life-threatening
presentations. Studies have shown that
anti-neuronal abs are more frequently found
in the blood & CSF
of Neuropsychiatric Lupus Erythematosus
(NPLE) patients to a much greater frequency
than in SLE patients without NPLE.
|
Methodology: |
FC |
Specimen
Requirement: |
1 mL Serum or CSF |
| CPT
Code: |
88180 |
Test
#: |
156 |
|
|
|
|
|
|
 |
TOP |
| |
|
|
| Anti-RNA Polymerase I/III IgG Abs |
Utilities: |
Autoantibodies to RNA
polymerases I, II and III are specific
for systemic sclerosis (Scleroderma – SSc),
particularly diffuse cutaneous SSc. Clinical
features associated with the presence of
these autoantibodies include a high frequency
of heart and kidney involvement and poor
survival 5 years after the first visit.
|
Methodology: |
EIA |
Specimen
Requirement: |
1 mL Serum or EDTA Plasma |
| CPT
Code: |
83520 |
Test
#: |
149 |
|
|
|
|
|
|
 |
TOP |
| |
|
|
| Cartilage
Oligomeric Matrix Protein (COMP) |
| Utilities: |
COMP was first described in cartilage,
tendons and synovial membranes. It is well
documented that when articular cartilage
matrix is degraded by a disease process,
protein fragments are produced and diffuse
out into the joint fluid. Some of these
proteins, such as COMP, subsequently appear
in the blood circulation and can be used
to monitor the progress of cartilage degradation
in inflammatory joint diseases.
The elevated COMP level is an aid in
identifying aggressive destruction of joint
tissue in diseases such as rheumatoid arthritis.
The COMP serum level is highly correlated
to the severity of arthritis and also to
clinical joint score and histopathological
signs of cartilage erosion. COMP serum
concentration can be used to assess cartilage
degradation in inflammatory joint diseases
and to help guide treatment decisions.
Results less than or equal to 15 U/L suggest
decreased risk for cartilage degradation.
Results greater than 15 U/L suggest increased
risk for aggressive cartilage destruction. |
| Methodology: |
EIA |
| Specimen Requirement: |
1 mL Serum (Minimum: 0.5 mL), ambient,
refrigerated or frozen |
| Normal Range: |
<15 U/L |
| CPT
Code: |
86235 |
| Test #: |
157 |
|
|
|
|
|
|
 |
TOP |
| |
|
|
| Utilities: |
The U3 RNP particle is
thought to participate in the pre-ribosomal
RNA processing. Anti-U3 RNP Abs have been
shown to be highly specific for patients
with SSc.
|
| Methodology: |
IPP |
| Specimen
Requirement: |
1 mL Serum or EDTA Plasma |
| CPT
Code: |
86235 |
| Test
#: |
232 |
 |
|
|
|
|
|
 |
TOP |
| |
|
|
| Mi-2,
PL-7, PL-12, EJ, OJ, Ku and U2 snRNP |
| Utilities: |
The idiopathic inflammatory
myopathies (IIM) are a heterogeneous group
of disorders characterized by muscle weakness
resulting from chronic muscle inflammation
of unknown cause. Patients with IIM have
a variety of autoantibodies with various
clinical utilities. One group of these
autoantibodies, which is found only in
patients with myositis, is known as myositis
specific autoantibodies (MSA). The myositis
antibodies have been shown to be highly
specific for patients with polymyositis,
dermatomyositis and overlap. |
| Methodology: |
IPP |
| Specimen
Requirement: |
1 mL Serum or EDTA Plasma |
| CPT
Code: |
86235 |
| Details: |
| Mi-2 |
PL-7 |
PL-12 |
EJ |
OJ |
Ku |
U2 snRNP |
|
| Test
#: |
| 237 |
238 |
239 |
276 |
277 |
279 |
234 |
|
 |
|
|
|
|
|
 |
TOP |
| |
|
|
| Utilities: |
The idiopathic inflammatory
myopathies (IIM) are a heterogeneous group
of disorders characterized by muscle weakness
resulting from chronic muscle inflammation
of unknown cause. Patients with IIM have a variety of autoantibodies with various
clinical utilities. One group of these autoantibodies which is found only in
patients with myositis, is known as myositis specific autoantibodies (MSA).
The myositis antibodies have been shown to be highly specific for patients
with polymyositis, dermatomyositis and overlap.
The Myositis Ab Panel is performed with
in-house bioassays which will be labeled
as “analytic specific reagents” (ASR). |
| Methodology: |
IPP - Immunoprecipitation |
| Specimen
Requirement: |
3 mL Serum, ambient, refrigerated
or frozen. (EDTA plasma can be used) |
| CPT
Code: |
86235 X 7 |
| Tests
in Panel: |
Mi-2, PL-7, PL-12, EJ,
OJ, Ku, U2 snRNP |
| Test
#: |
235 |
 |
|
|
|
|
|
 |
TOP |
| |
|
|
| Utilities: |
The idiopathic inflammatory
myopathies (IIM) are a heterogeneous group
of disorders characterized by muscle weakness
resulting from chronic muscle inflammation
of unknown cause. Patients with IIM have a variety of autoantibodies with various
clinical utilities. One group of these autoantibodies which is found only in
patients with myositis, is known as myositis specific autoantibodies (MSA).
The myositis antibodies have been shown to be highly specific for patients
with polymyositis, dermatomyositis and overlap.
The Myositis Ab Panel is performed with
in-house bioassays which will be labeled
as “analytic specific reagents” (ASR). |
| Methodology: |
IPP & ID - Immunoprecipitation |
| Specimen
Requirement: |
3 mL Serum
, ambient, refrigerated or frozen. (EDTA plasma can be used)
|
| CPT
Code: |
86235 X 9 |
| Tests
in Panel: |
Mi-2, PL-12, PL-7, EJ,
OJ, Ku, U2 snRNP, PM/Scl (ID) and Jo-1
(ID) |
| Test
#: |
236 |
| Turnaround
Time: |
14 days |
 |
|
|
|
|
|
 |
TOP |
| |
|
|
| Utilities: |
The Th/To Ab is present
in 10-19% of patients with Diffuse Cutaneous
Systemic Scleroderma (SSc) and in 3% of
patients with primary Raynaud’s
Disease. It has been shown to be highly
specific for patients with SSc.
|
| Methodology: |
IPP |
| Specimen
Requirement: |
1 mL Serum or EDTA Plasma |
| CPT
Code: |
86235 |
| Test
#: |
233 |
 |
|
|
|
|
|
 |
TOP |
| |
|
|
| Vitamin D, 25-Hydroxy (Calciferol) |
| Utilities: |
Vitamin D originates from
dietary and endogenous sources and is converted
to 25-hydroxy Vitamin D in the liver. Serum concentration of 25-hydroxy Vitamin
D is the most reliable measure of overall Vitamin D status. The result can rule
out Vitamin D deficiency as the cause of bone disease. Deficiencies of 25-hydroxy
Vitamin D may be secondary to dietary deficiency, malabsorption, liver disorder
or nephrotic syndrome. Elevated concentrations may be observed with excessive
intake of the vitamin, or food rich in Vitamin D.
|
| Methodology: |
RIA |
| Specimen
Requirement: |
1 mL Serum (Minimum: 0.5
mL), ambient, refrigerated or frozen |
| CPT
Code: |
- - - |
| Normal
Range: |
9.2 - 60.0 Ng/mL
|
| Test
#: |
148 |
 |
|
|
|
|
|
 |
TOP |
|
|